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Abstract 
 
Background 
 
There is limited evidence on the safety of direct oral anticoagulants (DOACs) in real 
world settings. 
 
Aim  
 
To investigate risks of bleeding and all-cause mortality in DOACs compared to warfarin. 
Method  
Prospective cohorts of incident oral anticoagulant users between 2011 and 2016 derived 
from two UK databases (QResearch and CPRD) linked to hospital and mortality data, 
with no anticoagulant prescriptions in the year before entry, were selected. Overall, 
132,231 warfarin, 7744 dabigatran, 37,863 rivaroxaban, and 18,223 apixaban users, 
were sub-grouped into those with atrial-fibrillation (AF) and without (non-AF), followed 
up until any major bleed leading to hospital admission or death. Analyses were adjusted 
for demographics, life style, comorbidities and prescribed medications. 
 
Results 
 
Compared to warfarin, apixaban was associated with decreased risk of major bleeding 
(hazard ratio 0.62, 95% confidence interval [CI] = 0.54 to 0.73), intracranial (HR 0.48, 
95% CI = 0.34 to 0.68) and gastro-intestinal (HR 0.67, 95% CI = 0.54 to 0.83). 
Dabigatran and rivaroxaban were associated with decreased risk of intracranial bleeding 
(HR 0.44, 95% CI = 0.27 to 0.71; HR 0.73, 95% CI = 0.59 to 0.90). Rivaroxaban was 
associated with increased risk of all-cause mortality (HR 1.34, 95% CI = 1.26 to 1.42), 
consistent for both sub-cohorts. A small increased all-cause mortality risk for apixaban 
(HR 1.14, 95% CI = 1.05 to 1.24) was statistically significant on the lower doses (HR 
1.31, 95% CI = 1.19 to 1.45) but not on higher doses (HR 0.98, 95% CI = 0.87 to 
1.10). 
 
Conclusion  
 
Overall, apixaban was found to be the safest drug for any major bleed, particularly for 
patients with increased risk of intracranial or gastro-intestinal bleeding. 
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